ImageneBio, Inc. — Director's Dealing 2022

Feb 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2022-02-02

Reporting Person: Zhang Xiaoyan Michelle (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-02	Stock Option (Right to Buy)	$11.45	A	40000	Acquired	2032-02-02	Common Stock (40000)	Direct

Footnotes

F1: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.